About Osivax
Osivax is a company based in Lyon (France) founded in 2017. Osivax has raised $42.21 million across 9 funding rounds from investors including Gates Foundation, Bpifrance and Meiji Group. Osivax offers products and services including oligoDOM TM, OVX836, and OVX033. Osivax operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Vir Biotechnology, Biological E and Freeline, among others.
- Headquarter Lyon, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$42.21 M (USD)
in 9 rounds
-
Latest Funding Round
$10.45 M (USD), Series B
Mar 04, 2025
-
Investors
Gates Foundation
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Osivax
Osivax offers a comprehensive portfolio of products and services, including oligoDOM TM, OVX836, and OVX033.
Platform technology for developing vaccines against mutating pathogens.
Vaccine candidate targeting influenza through T-cell responses.
Vaccine candidate for coronavirus infections using nanoparticle approach.
Funding Insights of Osivax
Osivax has successfully raised a total of $42.21M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $10.45 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $10.5M
-
First Round
First Round
(15 Jun 2017)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Series B - Osivax | Valuation |
investors |
|
| Dec, 2023 | Amount | Grant - Osivax | Valuation |
investors |
|
| Mar, 2023 | Amount | Grant - Osivax | Valuation |
investors |
Investors in Osivax
Osivax has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Bpifrance and Meiji Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Founded Year | Domain | Location | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Dairy products are produced and marketed by Meiji Group.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Osivax
Financial Statements - Osivax
Osivax Comparisons
Competitors of Osivax
Osivax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Vir Biotechnology, Biological E and Freeline, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
Frequently Asked Questions about Osivax
Osivax was founded in 2017.
Osivax is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Osivax is a funded company, having raised a total of $42.21M across 9 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on Jun 15, 2017.
Osivax was founded in 2017 in Lyon, France, within the biotechnology sector focused on vaccine development. Proprietary oligoDOM nanoparticle technology is utilized to elicit T-cell responses against constantly mutating pathogens. Operations center on advancing candidates like OVX836, which targets influenza and coronavirus. Research and development activities are conducted to address challenges in pathogen evolution and immune response enhancement.
Osivax's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Osivax offers oligoDOM TM, OVX836, and OVX033.
Osivax has 8 investors. Key investors include Gates Foundation, Bpifrance, Meiji Group, European Union, and Anaxago.